Alligator Bioscience AB (publ)

BATS-CHIXE:ATORXS Stock Report

Market Cap: SEK 384.7m

Alligator Bioscience Valuation

Is ATORXS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ATORXS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ATORXS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ATORXS's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ATORXS?

Key metric: As ATORXS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ATORXS. This is calculated by dividing ATORXS's market cap by their current revenue.
What is ATORXS's PS Ratio?
PS Ratio9.5x
SalesSEK 40.45m
Market CapSEK 384.75m

Price to Sales Ratio vs Peers

How does ATORXS's PS Ratio compare to its peers?

The above table shows the PS ratio for ATORXS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.1x
AREC Arecor Therapeutics
5.8x35.2%UK£28.3m
TRX Tissue Regenix Group
1.6x15.1%UK£40.6m
AVCT Avacta Group
8.1x0.4%UK£179.3m
PBX ProBiotix Health
5xn/aUK£10.3m
ATORXS Alligator Bioscience
9.5x55.6%SEK 384.7m

Price-To-Sales vs Peers: ATORXS is expensive based on its Price-To-Sales Ratio (9.5x) compared to the peer average (7x).

Price to Sales Ratio vs Industry

How does ATORXS's PS Ratio compare vs other companies in the GB Biotechs Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
GNS Genus
1.7x3.5%US$1.42b
OXB Oxford Biomedica
4.6x21.0%US$556.01m
TRX Tissue Regenix Group
1.6x15.1%US$51.02m
VRCI Verici Dx
2.4x78.8%US$10.29m
No. of Companies8PS020406080100+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: ATORXS is good value based on its Price-To-Sales Ratio (9.5x) compared to the UK Biotechs industry average (17.2x).

Price to Sales Ratio vs Fair Ratio

What is ATORXS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ATORXS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio9.5x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate ATORXS's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€62.90

7D

1.0%

1Y

13.3%

hVIVO

UK£149.7m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.22

7D

-13.4%

1Y

17.3%

Regeneron Pharmaceuticals

US$79.4b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$748.39

7D

-1.6%

1Y

-6.1%